Featured Press Release AVITA Medical Reports Third Quarter Results November 5, 2026 Learn More : AVITA Medical Reports Third Quarter Results
Featured Press Release AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027 November 5, 2026 Learn More : AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027
Nov 5, 2026 AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027
Sep 2, 2026 AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
Aug 18, 2026 AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
Aug 6, 2026 AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
Jun 18, 2026 AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
Apr 29, 2026 AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO
Apr 15, 2026 AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association
Apr 14, 2026 AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting
Apr 8, 2026 AVITA Medical Secures 10-Year BARDA Agreement Worth Up to $25.5M to Bolster U.S. Burn Emergency Preparedness
Apr 7, 2026 AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data
Jan 25, 2026 Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies
Jan 13, 2026 AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook
Nov 3, 2025 Data Presented at the 2025 Southern Region Burn Conference Reinforce RECELL® System as a Standard of Care in Acute Wound Treatment
Oct 1, 2025 CMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds
Sep 4, 2025 Real-World Data Shows Significant Reduction in Hospital Stay Using AVITA Medical’s RECELL® System
Aug 7, 2025 AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation
Aug 6, 2025 AVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to its Board of Directors and Transition of Board Chair Role to Cary Vance
Jun 9, 2025 AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL
Jun 5, 2025 AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™
Jun 3, 2025 AVITA Medical’s RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards
Mar 17, 2025 AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific
Jan 7, 2025 AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance
Dec 23, 2024 AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds
Dec 19, 2024 AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market
Nov 12, 2024 AVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand
Sep 10, 2024 AVITA Medical to Participate in Lake Street’s 8th Annual Best Ideas Growth (BIG8) Conference
Jul 1, 2024 AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary
Feb 29, 2024 AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement
Feb 22, 2024 AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
Jan 10, 2024 AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update
Nov 9, 2023 AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year
Nov 9, 2023 AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe
Oct 18, 2023 AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives
Sep 25, 2023 AVITA Medical Receives Best Product Award at the American Association for the Surgery of Trauma
Jun 16, 2023 AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients
Jun 7, 2023 AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects
Feb 23, 2023 AVITA Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance
Feb 9, 2023 AVITA Medical to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide 2023 Financial Guidance
Jan 19, 2023 AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call
Dec 12, 2022 AVITA Medical Submits FDA PMA Supplement to Further Expand Indication to Soft Tissue Repair
Nov 9, 2022 AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair
Sep 12, 2022 AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL® System
Aug 17, 2022 RECELL® System Data to be Presented at the Controversies and Conversations in Laser & Cosmetic Surgery Annual Meeting
Aug 11, 2022 AVITA Medical Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries using the RECELL® System
May 9, 2022 RECELL® System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting
Mar 23, 2022 RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium
Mar 21, 2022 AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction
Mar 2, 2022 Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL® System to Hospitals and Health Systems Across the U.S.
Feb 28, 2022 AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results
Feb 23, 2022 The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company
Feb 15, 2022 AVITA Medical to Announce Transition Period July 1, 2021 to December 31, 2021 Financial Results
Feb 2, 2022 AVITA Medical to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Jan 24, 2022 RECELL® System Data to be Presented at 44th Annual John A. Boswick Burn & Wound Care Symposium
Jan 10, 2022 AVITA Medical Announces Preliminary Unaudited Results for the Quarter ended December 31, 2021
Jan 6, 2022 AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Soft-Tissue Reconstruction
Jan 6, 2022 AVITA Medical Establishes Proof of Concept for Novel Treatments Using Genetically-Modified Skin Cells
Dec 15, 2021 AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation of Stable Vitiligo
Nov 3, 2021 AVITA Medical Announces Expanded Medicare Reimbursement to Outpatient Hospital and Ambulatory Surgical Centers
Oct 28, 2021 Regional Burn Conferences Feature 12 RECELL® System Data Presentations by Prominent Burn Surgeons
Aug 16, 2021 FDA Approves IDE Amendment to a Single-Arm Design for AVITA Medical’s Pivotal Study of the RECELL® System for Vitiligo Treatment
Jun 10, 2021 U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients
Apr 15, 2021 New RECELL® System Data to be Presented at 43rd Annual John A. Boswick Burn & Wound Care Symposium
Mar 30, 2021 15 RECELL® System Abstracts Accepted for Presentation at 53ʳᵈ Annual American Burn Association Meeting
Feb 3, 2021 AVITA Medical to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Dec 15, 2020 RECELL® System Data Presented at American Burn Association Fall Regional Burn Conferences
Nov 18, 2020 AVITA Therapeutics to Participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 9, 2020 AVITA Therapeutics and the Houston Methodist Research Institute Enter into Collaboration to Explore Novel Approaches for Skin Rejuvenation
Nov 5, 2020 Avita Therapeutics, Inc. Announces Correction of Time for the Adjourned 2020 Annual Stockholder Meeting
Nov 3, 2020 AVITA Therapeutics Announces Date Change for First Quarter 2021 Earnings Release and Conference Call
Sep 14, 2020 First Patient Enrolled in AVITA Therapeutic’s Pivotal Study Evaluating the RECELL System for Repigmentation of Stable Vitiligo
Jul 29, 2020 AVITA Therapeutics to Participate at the Canaccord Genuity 40th Annual Growth Conference
Jul 9, 2020 AVITA Therapeutics Provides Company Update and Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2020
Jun 29, 2020 AVITA Medical Limited Implementation of the Scheme of Arrangement to Redomicile from Australia to the United States of America
Jun 22, 2020 AVITA Medical Limited Proposed Redomiciliation to the United States of America – Court Approves Scheme of Arrangement
Jun 14, 2020 Proposed redomiciliation to the United States of America Chair’s address to Scheme Meeting
Jun 9, 2020 Proposed redomiciliation to the United States of America – Scheme Meeting on Monday, 15 June 2020 at 9.00am (AEST)
Jun 4, 2020 Proposed redomiciliation to the United States of America – Satisfaction of FIRB Condition
Jun 1, 2020 AVITA Medical Files RECELL® System Investigational Device Exemption (IDE) Application with the U.S. Food and Drug Administration for Treatment of Vitiligo
May 11, 2020 Proposed redomiciliation to the United States of America – Federal Court of Australia orders convening of Scheme Meeting
Apr 5, 2020 AVITA Medical Provides Preliminary Top Line Results for the Third Quarter and COVID-19 Update
Apr 1, 2020 RECELL® System Data Accepted to 52nd Annual American Burn Association Meeting Available Online
Mar 4, 2020 First Patient Enrolled in AVITA Medical’s Pivotal Study Evaluating RECELL® System for Pediatric Scald Injuries
Mar 2, 2020 First Patient Enrolled in AVITA Medical’s Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction
Dec 29, 2019 AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL System for Vitiligo
Nov 24, 2019 AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus Enter into Collaboration to Explore Potential Spray-On Treatment of Genetically Modified Cells for Epidermolysis Bullosa
Nov 12, 2019 AVITA Medical Announces Institutional Placement of A$120.0 Million to Support Commercial Growth and Pipeline Development
Sep 18, 2019 New Data Published in AESTHETIC PLASTIC SURGERY Explores the Use of the RECELL® System in Combination with Dermabrasion to Treat Acne Scars
Sep 16, 2019 AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Pivotal Study Evaluating RECELL® System for Soft Tissue Reconstruction
Jun 30, 2019 RECELL® System Feasibility Study Results for Treatment of Diabetic Foot Ulcers Presented at 11th Annual Congress of the Japanese Society of Limb Salvage & Podiatric Medicine
Jun 11, 2019 AVITA Medical Announces RECELL® System Preliminary Data Focused on Vitiligo and Facial Acne Scars at the 24th Annual World Congress of Dermatology
May 15, 2019 Health Economic Model Published in Advances in Therapy Demonstrates Reduced Cost and Decreased Hospital Stay with the RECELL® System
Apr 8, 2019 AVITA Medical Announces Presentation at ABA Meeting Highlighting Results of Study Using RECELL® System to Treat Third-Degree Burns in Pediatric Patients
Apr 5, 2019 AVITA Medical RECELL® System Health Economic Data Projects USD $28 Million in Annual Savings at a Single Major Burn Center Versus Standard of Care
Mar 10, 2019 AVITA Medical Announces Ten RECELL® System Presentations at the American Burn Association (ABA) Annual Meeting
Mar 3, 2019 Avita Medical Announces Collaboration with COSMOTEC, an M3 Group Company, to Commercialize the RECELL® System in Japan
Jan 28, 2019 AVITA Medical Announces Nine RECELL® System Abstracts Accepted for Presentation at American Burn Association (ABA) 51st Annual Meeting
Dec 3, 2018 AVITA Medical Announces Institutional Placement of A$40.0 Million to Support Commercialization and Pipeline Advancement
Nov 15, 2018 AVITA Medical Announces Hiring of Full U.S. Sales Team of Experienced Burn Professionals to Support National Launch of RECELL® System
Nov 12, 2018 Leading Burn Surgeons Present Positive RECELL® System Results at 31st Annual Southern Region Burn CME Conference and Northeast Region Burn Conference
Oct 24, 2018 AVITA Medical Announces Commencement of Randomized Controlled Clinical Study of RECELL® System in Treatment of Children with Burn Injuries
Oct 17, 2018 AVITA Medical Announces First U.S. Sales of RECELL® System and Commencement of Commercial Shipping
Oct 15, 2018 AVITA Medical Announces Medical Education Symposium and Presentation of RECELL® System Pivotal Trial Results at U.S. Midwest Region Burn Conference
Sep 26, 2018 AVITA Announces Presentation of RECELL System Effectiveness and Safety at Eastern Great Lakes Burn Conference
Sep 25, 2018 20180925_AVITA-Medical-Announces-Receipt-of-1-Million-Research-and-Development-Tax-Credit
Sep 20, 2018 AVITA Medical Announces FDA Approval of the RECELL® System for the Treatment of Severe Burns in the U.S.
Aug 23, 2018 AVITA Medical Announces Commencement of Manufacturing of RECELL® Device in Newly Acquired Facility in Preparation for Planned U.S. Launch
Aug 22, 2018 AVITA Medical Announces Presentation of RECELL® Device Effectiveness and Safety in Treatment of Thermal Burns at Premier U.S. Military
Jul 20, 2018 AVITA Medical Announces Expansion of Management Team to Support Planned U.S. Launch of RECELL® Device
Jun 28, 2018 AVITA Medical Announces Acquisition of Manufacturing Facility to Support Planned U.S. Launch of RECELL® Device
Jun 27, 2018 AVITA Medical Announces Presentation of RECELL® Device Clinical Trial Results at Changhai Academic Week for Burns Treatment Conference in China
Jun 26, 2018 AVITA Medical RECELL® Device Pivotal Trial Results in Second-Degree Burns Published in Journal of Burn Care & Research
Jun 6, 2018 AVITA Medical Announces Institutional Placement of A$16.0 Million to Support U.S. Commercialization of the RECELL® Device
Jun 6, 2018 AVITA Medical Announces Expanded Compassionate Use of RECELL® Device in Life-Threatening Burns
May 22, 2018 AVITA Medical Announces Presentation at ISPOR Meeting Validating Acute Burn Health Economic Model
Mar 26, 2018 AVITA Medical Announces RECELL® Health Economic Model to be Presented at ISPOR 23rd Annual International Meeting
Mar 22, 2018 AVITA Medical Announces MIHS Burn Center Press Conference Regarding RECELL® Treatment of Patient with Necrotizing Fasciitis (Flesh Eating Bacteria)
Feb 12, 2018 AVITA Medical Announces FDA Approval of Expansion of RECELL Compassionate Use Program in Life Threatening Injuries
Jan 30, 2018 Avita Announces Five RECELL® Abstracts Accepted for Presentation at American Burn Association (ABA) 50th Annual Meeting
Dec 5, 2017 Avita Announces New Chief Financial Officer; Existing CFO Moves to Chief Administrative Officer
Oct 26, 2017 Breakthrough medical and pharmaceutical funding awarded to consortium that partners Avita Medical with 20 other organisations across Australia
Oct 4, 2017 U.S. FDA Approves New Continued Access Protocol for the ReCell® Device for Treatment of Burn Injuries
Sep 28, 2017 Avita Medical Announces Submission of U.S. FDA Premarket Approval (PMA) Application for the ReCell® Device for Treatment of Burn Injuries
May 10, 2017 Initial Pre-Emergency Use Authorization submission made to U.S. FDA for use of ReCell® in a Mass Casualty Scenario
Jan 25, 2017 Avita Medical to Participate in the 3rd annual Biotech and Money / Medtech and Money London 2017 Conference